STERIS Agrees $2.1 Billion Debt-Funded Purchase of Xodus Medical
STERIS Corporation has agreed to acquire all the equity of Xodus Medical for $2.1 billion. The agreement was disclosed on Oct. 12, 2026, with STERIS as buyer and Xodus Medical as target. Investing.com
The purchase covers 100% of the equity. Control will be complete. That structure leaves no minority stub and consolidates economic interest and voting power in STERIS from closing, subject only to the transaction closing as announced. STERIS
Financing is expected to be primarily debt. The close is anticipated by December 31, 2026. Yahoo Finance The calendar is tight. Announcement to anticipated close spans roughly eleven weeks, compressing the execution window for funding, settlement and transfer of the equity.
STERIS is a leading provider of infection prevention and other procedural products and services. STERIS The stated acquirer is STERIS Corporation under the terms of the agreement, with the acquisition framed as an equity purchase rather than an asset purchase.
For a balance-sheet reader, the funding choice is the central variable. A primarily debt-funded, all-equity acquisition increases leverage at close without increasing share count. That preserves existing equity holders' proportional ownership but substitutes fixed debt service and refinancing exposure for the dilution that an equity issue would create. The qualifier primarily matters. It indicates debt will carry most of the $2.1 billion purchase price, while leaving room for cash on hand or other sources for the remainder, though the split was not specified in the disclosed terms. Credit work now turns on tenor, pricing, covenants and whether permanent financing is in place at signing or must be arranged before year-end.
Looking at what this means for execution, the price certainty cuts one way and the funding cuts the other. A fixed $2.1 billion equity price removes purchase-price variability for modeling. Debt funding concentrates attention on debt-market capacity and syndication risk between mid-October and late December. A short interim period reduces the time the capital structure is in limbo. It also reduces flexibility if market conditions shift, since there is limited runway to renegotiate or replace facilities before the anticipated Dec. 31 close date.
In my view, the thin disclosure puts the focus on cash conversion after close. With leverage rising, the relevant questions for holders of STERIS credit and equity are the speed of deleveraging, the stability of operating cash flow from the combined consumables and procedural base, and the allocation of free cash flow between debt repayment, capital expenditure and distributions. None of those inputs were part of the verified announcement terms. What is known is the direction of travel: larger enterprise, higher gross debt, full ownership of Xodus Medical if the transaction closes on schedule.
